Evidence map›Paper›PMID 38892474›Full record

ArticleInternational journal of molecular sciences2024

O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy.

Wenkang Dong, Laraib Imdad, Shengnan Xu, Yinli Wang, Chengzhi Liu, Shiyu Song, Zechuan Li, Ying Kong, Li Kong, Xiang Ren

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenkang DongDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Laraib ImdadDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Shengnan XuDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Yinli WangDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Chengzhi LiuDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Shiyu SongDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Zechuan LiDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Ying KongKey Laboratory of Reproductive and Developmental Biology, Dalian Medical University, Dalian 116044, China.
Li KongDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Xiang RenDepartment of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.ORCID 0000-0002-2962-1922

Funding

Liaoning Provincial Education Department LJKQZ20222389Natural Science Foundation of Liaoning Province 2020-BS-189
6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.

Indexed as

AcetylglucosamineAMP-Activated Protein KinasesDiabetes Mellitus, ExperimentalDiabetic RetinopathyN-AcetylglucosaminyltransferasesAnimalsApoptosisbeta-N-AcetylhexosaminidasesCell LineHumansMaleMetforminMiceMice, Inbred C57BLRetinaAcetylglucosamineAMP-Activated Protein Kinasesbeta-N-Acetylhexosaminidaseshexosaminidase CMetforminN-AcetylglucosaminyltransferasesO-GlcNAc transferaseAMPKapoptosisdiabetic retinopathyO-GlcNAc modificationphotoreceptor

Identifiers

PMID38892474
PMCPMC11173153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.